The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...

Une étude confirme l’absence de risque majeur lié au vaccin Abrysvo de Pfizer pour les femmes enceintes et leurs fœtus, dans ...

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

(Reuters) -Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% ...

Unseasonably high flu cases are leading to an uptick in visits to NSW emergency departments while COVID continues to increase ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

A proposed bill in South Carolina is stirring new controversy over the COVID-19 vaccine. If passed, the bill would require ...

Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...